resveratrol has been researched along with dexrazoxane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, JM; Lee, JH; Wendorff, TJ | 1 |
| Al-Hussaniy, HA; Al-Samydai, AM; Al-Tameemi, ZS; Al-Zobaidy, MAJ; Alburghaif, AH; Alkhafaje, Z; Alkuraishy, HM; Azam, F; Mostafa-Hedeab, G; Naji, MA | 1 |
1 review(s) available for resveratrol and dexrazoxane
| Article | Year |
|---|---|
Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs.
Topics: Anthracyclines; Antineoplastic Agents; Cardiotoxicity; Dexrazoxane; Digoxin; Humans; Polyketides; Resveratrol | 2023 |
1 other study(ies) available for resveratrol and dexrazoxane
| Article | Year |
|---|---|
Resveratrol: A novel type of topoisomerase II inhibitor.
Topics: Adenosine Triphosphatases; Allosteric Regulation; Amino Acid Substitution; Dexrazoxane; DNA Topoisomerases, Type II; Humans; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Poly-ADP-Ribose Binding Proteins; Protein Interaction Domains and Motifs; Protein Multimerization; Resveratrol; Saccharomyces cerevisiae Proteins; Topoisomerase II Inhibitors | 2017 |